In 2010, funded by $24 million from the federal stimulus package, the ADNI study continued through ADNI GO. Building on the momentum of ADNI, ADNI GO employed the standardized approach of previous ADNI work. ADNI GO was the first study of its kind to focus on participants who exhibit the very beginning stages of memory loss. Its 200 subjects with eMCI (early MCI) is helping to more fully understand AD progression in its earliest stages.
In 2011 ADNI2 was launched for an additional $70 million. ADNI2 is performing amyloid imaging, and multimodal MRI imaging together with lumbar puncture for cerebrospinal fluid, genetics, and clinical/cognitive assessments on normal elders, those with mild memory problems and patients with dementia due to Alzheimer's disease. The ADNI project in the USA has led to the World Wide ADNI including projects in Japan, Australia, Europe, China, Taiwan, and Korea. More than 300 publications have emerged from ADNI.
The FNIH coordinates the fundraising efforts for ADNI and has raised more than $45 million from the private sector.
For more information about the PPSB, contact Erika Tarver at firstname.lastname@example.org or or Alison Drone at email@example.com.
Established by the United States Congress to support the mission of the
NIH—improving health through scientific discovery in the search for cures—the
Foundation for the NIH is a leader in identifying and addressing complex
scientific and health issues. The Foundation is a non-profit, 501(c)(3)
charitable organization that raises private-sector funds for a broad portfolio
of unique programs that complement and enhance the NIH priorities and
activities. For additional information about the Foundation for the NIH, please
The Private Partner Scientific Board (PPSB) serves as an independent, open, and
pre-competitive forum for all private-sector partners in ADNI to collaborate,
share information, and offer scientific and private-sector perspectives and
expertise on issues relating to the project. The PPSB is convened by the
Foundation for the NIH (FNIH).
The members of the ADNI Private Partner Scientific Board (PPSB) that helps fund ADNI include:
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) National Institutes of Health Grant U01 AG024904.
Expand / collapse
ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Amorfix, Bayer Schering Pharma AG, Bioclinica Inc., Biogen Idec, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, Innogenetics, IXICO, Janssen Alzheimer Immunotherapy, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Meso Scale Diagnostic, & LLC, Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Servier, Synarc, Inc., and Takeda Pharmaceuticals, as well as non-profit partners the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration.
Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation.
ADNI PI Michael Weiner Conflict List Summer 2012